Explore recent issues of Contract Pharma covering key industry trends.
Read the full digital version of our magazine online.
Behind every facility expansion, technology investment, and quality milestone in the CDMO sector is a leadership team making deliberate choices about where to focus, how to grow, and when to take calculated risks.
Stay informed! Subscribe to Contract Pharma for industry news and analysis.
Get the latest updates and breaking news from the pharmaceutical and biopharmaceutical industry.
Discover the newest partnerships and collaborations within the pharma sector.
Keep track of key executive moves and promotions in the pharma and biopharma industry.
Updates on the latest clinical trials and regulatory filings.
Stay informed with the latest financial reports and updates in the pharma industry.
A video roundup of the week’s top industry news stories.
Expert Q&A sessions addressing crucial topics in the pharmaceutical and biopharmaceutical world.
In-depth articles and features covering critical industry developments.
Access exclusive industry insights, interviews, and in-depth analysis.
Insights and analysis from industry experts on current pharma issues.
A one-on-one video interview between our editorial teams and industry leaders.
Listen to expert discussions and interviews in pharma and biopharma.
Contract Pharma Stream offers a centralized destination where users can watch expert-led sessions anytime, anywhere
A detailed look at the leading US players in the global pharmaceutical and BioPharmaceutical industry.
Browse companies involved in pharmaceutical manufacturing and services.
Comprehensive company profiles featuring overviews, key statistics, services, and contact details.
A comprehensive glossary of terms used in the pharmaceutical and biopharmaceutical industry.
Watch in-depth videos featuring industry insights and developments.
Download in-depth eBooks covering various aspects of the pharma industry.
Access detailed whitepapers offering analysis on industry topics.
View and download brochures from companies in the pharmaceutical sector.
Explore content sponsored by industry leaders, providing valuable insights.
Stay updated with the latest press releases from pharma and biopharma companies.
Explore top companies showcasing innovative pharma solutions.
Meet the leaders driving innovation and collaboration.
Engage with sessions and panels on pharma’s key trends.
Hear from experts shaping the pharmaceutical industry.
Join online webinars discussing critical industry topics and trends.
A comprehensive calendar of key industry events around the globe.
Live coverage and updates from major pharma and biopharma shows.
Find advertising opportunities to reach your target audience with Contract Pharma.
Review the editorial standards and guidelines for content published on our site.
Understand how Contract Pharma handles your personal data.
View the terms and conditions for using the Contract Pharma website.
What are you searching for?
Rúa do Vidro 117D, Parcelas 3-6, Lugo, , 27003, ES
Marks first ENHANZE agreement to include ADC targets.
By: Charlie Sternberg
How today’s manufacturers are filling the growing need for biologics without rushing complex processes in development or quality control.
By: Kristin Brooks
Advantages of integrated, QbD-guided formulation development services and key strategies for minimizing risk and maximizing success.
By: Eliza Yeung
Will help advance an ADC against an undisclosed target.
As trade policy, regulatory scrutiny, and capital discipline reshape biologics development, sponsors are rethinking where and how commercial manufacturing is secured. Bora Biologics’ recent U.S. expansion and validated 2,000L scale-up reflect a broader shift toward demand-aligned, inspection-ready commercial capacity in the markets where products will ultimately be supplied.
Released By Bora Biologics
Epicrispr’s investigational gene therapy, EPI-321, is a treatment for facioscapulohumeral muscular dystrophy.
By: Patrick Lavery
The partnership will work to advance Novelty Nobility’s bispecific antibody drug candidate through process development and GMP manufacturing.
Expands its capabilities in next-generation biologics with Cizutamig, Candid’s lead investigational asset.
Expansions at sites in both the United States and Europe are crucial to PCI’s vision for the coming years.
Released By PCI Pharma Services
Plans for GMP release for production by the end of 2026.
How logistics pathways adapt to liquid and lyophilized ADC formulations.
Released By Thermo Fisher Scientific Pharma Services
Marks the sixth consecutive year that WuXi Biologics has received this honor
Mabwell’s business partner in this agreement has not been identified.
Collaboration aims to enhance their customers' ADC development and manufacturing programs.
The designation certifies WuXi’s fitness for commercial manufacturing and quality management of drug-device combination products.
Enter the destination URL
Or link to existing content
Enter your account email.
A verification code was sent to your email, Enter the 6-digit code sent to your mail.
Didn't get the code? Check your spam folder or resend code
Set a new password for signing in and accessing your data.
Your Password has been Updated !
